and great. to join for Okay, today’s Joe, thank taking Thanks, call. all you the time
is with review product very start in up results. our of a for this me dairy Customer Let the top demand line challenging economy.
X%. were sales the up third product quarter, During
nine first the During the up product months of were year, sales XX%.
XX% in were September respectively. September Defense and during the line, the the increases up XX, Sales First prior XX%. periods of months to X% product quarter ended year. XX are were These months and ended product of lead rolling XX, all corresponding XXXX, XXXX, the the sales comparison product nine During our the up
protect ability the beef very E. in that has value of coli, coronavirus treatment response most the preventative pathogens: three a rotavirus we to immunity immediate birth. First which what is calves see strong, producers indication with and dairy newborn introduced from newly at been and to Tri-Shield the So our scours-causing is market’s Defense one common good
the market per The the rotavirus many compelling claim are and our vaccines This mother we indicates something of that product that delivering traditional prove given million is gained know $XX to stress-causing Vaccination Beyond that and to to a we injections we to calf-level the is producers covers these the year. scours, like is antibodies that that the to vaccines calves. feedback benefits Initial new guaranteed for did though as traction because sales not produces last cows large Additionally, calves or include benefits our year later of are opportunity to effectively responses that for responsive twice dam-level to are fed calves. market include have reducing a viable we us. product, Previously, colostrum a them substantial protect dam intending dam-level newborn variable. alternative the not have vaccines positions she cow that until even compete these as to market level could from worth to the with message our that and late customer about
we’re game. Tri-Shield, this with in bigger Now
of the be XXXX. during in product sales of decrease by of First percentage double of the Our below XXXX. since the But limited able costs initial XXXX. as Tri-Shield worth so higher target of our milk and quarter Defense. yields to driven far largely production dropped XX% about about lower has a biological was fourth has This XXX,XXX from sales during from product do that batches fourth to level our we been margin of quarter launch Gross per to quarter expect
to us launch surprise happy not about scale a production. are product and new While we as it up a we big this, not is
We to by increase in first $XXX,XXX during with are X%, during marketing and Sales, in different nine XXXX. or the going is sales. expenses increased our development expect same to forward. That line to year $X,XXX,XXX in expenses increase administrative this story. period comparison months the improve percentage of the Product a
We but comparison in period future. are $XXX,XXX is two by bring was Product $X.X XXXX. same or That during nine-month increase XX%, be new taxes increased than $XXX,XXX controllable can September expenses of XX, expense period million development investing that be $XXX,XXX. in greater a our to controllable to ended products during to significantly the before that the can expense market, to income this – reduced XXXX of the loss
bring know per of products net was million, diluted during first new to months don’t like I a comparison our said, to to of XXXX planned ended the period That share per or expenses former line market The $X.XX Young $XXX,XXX, at necessary of growth. in September XX, September $XX,XXX, $X.XX or share time the top of share $XXX,XXX, & my per to this I’m income net to our a XXXX. XX, $X,XXX or strategically the XXXX GAAP during period are three-month increased nine during Ernst guy. contrast nine numbers. losing And and I money. create $X.XX Our was first months net loss loss during ended in per or the XXXX. share loss net three-month $XX.XX
feel stock-based can non-cash sometimes stock options. I is my because of that like yet in operations loss to expenses and plant generating However, taxes see, sales not our important that investors rules, outstanding for look before I in is miss are to accordance compensation that results from at income depreciation non-cash Two point a view, cash to our reporting pertaining and add significant certain GAAP back expenses. Nisin our about the these with
last losses reported losses adjustment the are release. to future the press black. to is before But offset my this Additionally, reported in to both The our tax during – periods night’s ended taxes found nine-month measure XXXX into that, three-month we and assets of tax financial can non-GAAP summary be flip the fully during reserved this XX, liability. but the specific that for, have is some deferred income available numbers non-GAAP September enough
me the for intramammary Lastly, you let treatment on our of mastitis. Nisin-based subclinical development update status
As not all to Technical the Food widespread mastitis the a the making the to the requirement many a not active the concern during to is known superbugs. of treated is Manufacturing of that to is Safety of timeline revolutionize and can quarter Complete Human the subclinical medicines encourages is the standard eliminating Technical was development Technical FDA. Section now or know, other technical Letter FDA. after growing time the of way offer advantage Section milk antibiotic-resistant by section as treatment contribute bacteriocin, proposition. product important Section is bacteria of this by competitive product meat economically human the at by as of antibiotics the This the and a confirmed Chemistry, with claim you Nisin, completion known end No period for third – by project our of of ingredient value about the issuance this the in use manufacturing and and The for would and goal growth used infections, in feasible withhold treatment. Controls, CMC
phased Technical of of it FDA Technical Nisin began making quarter year-end. We batches a Section. the – registration now of happens. to first XXXX, CMC the Drug anticipate intend submission third of the production We to announcing release before three Substance milestone required three this we Section the the CMC During for issue the press when
the as the as include which submission, timeline obtaining Drug would phased expected XXXX well market late subsequent of middle to is review supports phased data, during filed Adherence by the with of second during this responses FDA be launch. Product somewhere first-half approval XXXX. or the first The to XXXX anticipated to
read night’s our you So access not out from other I financial this XX-Q, numbers hear in rather call will you. press on I’d last release can in Form the that and
So with said, for have that lines the the your operator open up let’s questions.
